Korea Yakult Co., Ltd., Yongin, Gyeonggi 449-901, South Korea.
World J Gastroenterol. 2013 Jan 14;19(2):274-83. doi: 10.3748/wjg.v19.i2.274.
To investigate the effect of novel probiotics on the clinical characteristics of high-fructose induced metabolic syndrome.
Male Wistar rats aged 4 wk were fed a 70% w/w high-fructose diet (n = 27) or chow diet (n = 9) for 3 wk to induce metabolic syndrome, the rats were then randomized into groups and administered probiotic [Lactobacillus curvatus (L. curvatus) HY7601 and Lactobacillus plantarum (L. plantarum) KY1032] at 10(9) cfu/d or 10(10) cfu/d or placebo by oral gavage for 3 wk. Food intake and body weight were measured once a week. After 6 wk, the rats were fasted for 12 h, then anesthetized with diethyl ether and sacrificed. Blood samples were taken from the inferior vena cava for plasma analysis of glucose, insulin, C-peptide, total-cholesterol, triglycerides and thiobarbituric acid-reacting substances. Real-time polymerase chain reaction was performed using mouse-specific Taqman probe sets to assess genes related to fatty acid β-oxidation, lipogenesis and cholesterol metabolism in the liver. Target gene expression was normalized to the housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase.
Rodents fed a high-fructose diet developed clinical characteristics of the metabolic syndrome including increased plasma glucose, insulin, triglycerides, total cholesterol and oxidative stress levels, as well as increased liver mass and liver lipids compared to chow fed controls. Probiotic treatment (L. curvatus HY7601 and L. plantarum KY1032) at high (10(10) cfu/d) or low dosage (10(9) cfu/d) lowered plasma glucose, insulin, triglycerides and oxidative stress levels. Only high-dose probiotic treatment reduced liver mass and liver cholesterol. Probiotic treatment reduced lipogenesis via down-regulation of SREBP1, FAS and SCD1 mRNA levels and increased β-oxidation via up-regulation of PPARα and CPT2 mRNA levels.
Probiotic L. curvatus HY7601 and L. plantarum KY1032 combined suppressed the clinical characteristics of high-fructose-induced metabolic syndrome, therefore, may provide a natural alternative for the treatment of diet-induced metabolic syndrome.
研究新型益生菌对高果糖诱导代谢综合征临床特征的影响。
4 周龄雄性 Wistar 大鼠喂食 70%w/w 高果糖饮食(n = 27)或标准饮食(n = 9)3 周,以诱导代谢综合征,然后将大鼠随机分为几组,通过口服灌胃分别给予益生菌[弯曲乳杆菌(L. curvatus)HY7601 和植物乳杆菌(L. plantarum)KY1032]10(9)cfu/d 或 10(10)cfu/d 或安慰剂 3 周。每周测量一次食物摄入量和体重。6 周后,大鼠禁食 12 小时,然后用乙醚麻醉处死。从下腔静脉取血样,检测血浆中葡萄糖、胰岛素、C 肽、总胆固醇、甘油三酯和硫代巴比妥酸反应物质。使用小鼠特异性 Taqman 探针组进行实时聚合酶链反应,以评估肝脏中与脂肪酸β-氧化、脂肪生成和胆固醇代谢相关的基因。靶基因表达与管家基因甘油醛-3-磷酸脱氢酶(glyceraldehyde-3-phosphate dehydrogenase)进行归一化。
喂食高果糖饮食的啮齿动物出现代谢综合征的临床特征,包括血浆葡萄糖、胰岛素、甘油三酯、总胆固醇和氧化应激水平升高,以及与标准饮食对照组相比肝质量和肝脂质增加。高剂量(10(10)cfu/d)或低剂量(10(9)cfu/d)益生菌(L. curvatus HY7601 和 L. plantarum KY1032)治疗可降低血浆葡萄糖、胰岛素、甘油三酯和氧化应激水平。只有高剂量益生菌治疗可降低肝质量和肝胆固醇。益生菌治疗通过下调 SREBP1、FAS 和 SCD1 mRNA 水平降低脂肪生成,并通过上调 PPARα 和 CPT2 mRNA 水平增加β-氧化。
益生菌 L. curvatus HY7601 和 L. plantarum KY1032 联合抑制高果糖诱导代谢综合征的临床特征,因此,可能为治疗饮食诱导的代谢综合征提供一种天然替代方法。